Sainz Maria 4

What Happened

• Maria Sainz, a director of Pulse Biosciences (PLSE), was granted two derivative equity awards on June 11, 2026: 30,000 shares and 3,793 shares. The reported acquisition price is $0.00, indicating these were awards (not open-market purchases) and no cash was paid at grant. The filing does not state an immediate cash value or sale of shares.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-15 (timely filing).
• Award amounts: 30,000 shares (derivative) and 3,793 shares (derivative); reported price $0.00.
• Shares owned after transaction: not specified in the filing.
• Vesting: 30,000-share award vests in equal monthly installments over one year, first vesting on July 11, 2026 (Footnote F1). The 3,793-share award vests in equal quarterly installments over one year, first vesting on September 5, 2026 (Footnote F2).
• No 10b5-1 plan, tax-withholding sale, or exercise-for-cash indicated in the filing.

Context

• These are compensation awards (derivative grants) that vest over time contingent on continued service; they are common director compensation and do not represent an open-market buy or sale. Because vesting is staggered, the awards do not result in immediate shares available for sale unless further actions (e.g., settlement or exercise) occur later.